The Journal of clinical endocrinology and metabolism · 2025
Continuous Glucose Monitoring in the Management of Congenital Hyperinsulinism: A National User-satisfaction Survey, UK.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Couch Helen, Pearson Andrew, Malhotra Neha, Ferguson Michael, Couch George, Gilbert Clare, Morgan Kate, Mann Sarah, Cassidy Kelly, Worthington Sarah, O'Shea Elaine, SalomonEstebanez Maria, Worth Chris, Senniappan Senthil, Banerjee Indraneel, Dastamani Antonia
Аннотация
CONTEXT: Congenital hyperinsulinism (CHI) causes severe and recurrent hypoglycemia with a 33% to 50% risk of neurodisability necessitating rigorous glucose monitoring. Continuous glucose monitoring (CGM) is now widely used in CHI with limited data on user-reported benefits. There are no validated instruments available to assess the impact of CGM use on quality of life (QOL) in CHI.
OBJECTIVE: To evaluate CGM user satisfaction of patients with CHI and their carers.
DESIGN: Modified CGM-satisfaction (CGM-SAT) and glucose monitoring surveys (GMS) were distributed electronically to CHI families using CGM.
SETTING: CHI highly specialized services, UK, May to August 2023.
PATIENTS OR OTHER PARTICIPANTS: Parents (n = 86) and teachers (n = 15) of patients with CHI using CGM (0-18 years old) and patients themselves if ≥7 years old (n = 20).
MAIN OUTCOME MEASURES: User-reported ease of CGM handling, influence of CGM on CHI management and QOL, and desire for continued use of CGM.
RESULTS: Most respondents reacted positively to statements regarding: CGM device handling (58% agreed or strongly agreed), influence on CHI management (70%), QOL (75%), and continued use (86%). Satisfaction with CGM was positively correlated with duration of use (r = 0.40, P < 0.001). Eighty-six percent of users reported checking the CGM 1 to 5 times per hour. Users reported perceived improvements in safety, hypoglycemia detection, freedom, and independence, despite concerns with accuracy and device range.
CONCLUSION: Patients with CHI and their carers reported that they feel safer and perceive benefits from CGM in all aspects of living with CHI.
OBJECTIVE: To evaluate CGM user satisfaction of patients with CHI and their carers.
DESIGN: Modified CGM-satisfaction (CGM-SAT) and glucose monitoring surveys (GMS) were distributed electronically to CHI families using CGM.
SETTING: CHI highly specialized services, UK, May to August 2023.
PATIENTS OR OTHER PARTICIPANTS: Parents (n = 86) and teachers (n = 15) of patients with CHI using CGM (0-18 years old) and patients themselves if ≥7 years old (n = 20).
MAIN OUTCOME MEASURES: User-reported ease of CGM handling, influence of CGM on CHI management and QOL, and desire for continued use of CGM.
RESULTS: Most respondents reacted positively to statements regarding: CGM device handling (58% agreed or strongly agreed), influence on CHI management (70%), QOL (75%), and continued use (86%). Satisfaction with CGM was positively correlated with duration of use (r = 0.40, P < 0.001). Eighty-six percent of users reported checking the CGM 1 to 5 times per hour. Users reported perceived improvements in safety, hypoglycemia detection, freedom, and independence, despite concerns with accuracy and device range.
CONCLUSION: Patients with CHI and their carers reported that they feel safer and perceive benefits from CGM in all aspects of living with CHI.